Attenuation of N‐nitrosodiethylamine‐induced liver fibrosis by high‐molecular‐weight fucoidan derived from Cladosiphon okamuranus
Authors:
- 18 November 2009
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 25 (10) , 1692-1701
Abstract
Background and Aim: Liver fibrosis is closely associated with the progression of various chronic liver diseases. Fucoidan exhibits different biological properties such as anti‐inflammatory, anti‐oxidant and anti‐fibrotic activities. The aim of this study was to determine whether oral fucoidan administration inhibits N‐nitrosodiethylamine (DEN)‐induced liver fibrosis.Methods: Liver fibrosis was induced in rats by injecting DEN (50 mg/kg). Rats were given 2% of crude fucoidan solution or 2% of high‐molecular‐weight (HMW) fucoidan solution. They were divided into a crude fucoidan group, an HMW fucoidan group, a DEN alone group, a DEN + crude fucoidan group, a DEN + HMW fucoidan group and a control group.Results: Liver fibrosis and hepatic hydroxyproline levels were significantly more decreased in the DEN + HMW fucoidan group than in the DEN‐alone group. Anti‐fibrogenesis was unremarkable in the DEN + crude fucoidan group. Hepatic messenger RNA levels and immunohistochemistry of transforming growth factor beta 1 were markedly increased by DEN. This increase was attenuated by HMW fucoidan. Hepatic chemokine ligand 12 expression was increased by DEN. This increase was suppressed by HMW fucoidan. HMW fucoidan significantly decreased the DEN‐induced malondialdehyde levels. Also, fucoidan markedly increased metallothionein expression in the liver. Fucoidan was clearly observed in the liver by immunohistochemical staining in HMW fucoidan‐treated rats, while it was faintly stained in the livers of crude fucoidan‐treated rats.Conclusion: These findings suggest that the HMW fucoidan treatment causes anti‐fibrogenesis in DEN‐induced liver cirrhosis through the downregulation of transforming growth factor beta 1 and chemokine ligand 12 expressions, and that scavenging lipid peroxidation is well‐incorporated in the liver.Keywords
This publication has 48 references indexed in Scilit:
- Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF‐β as major players and therapeutic targetsJournal of Cellular and Molecular Medicine, 2006
- Liver fibrosisJournal of Clinical Investigation, 2005
- Management of Cirrhosis and AscitesNew England Journal of Medicine, 2004
- Cirrhosis: new research provides a basis for rational and targeted treatmentsBMJ, 2003
- Liver fibrosis – from bench to bedsideJournal of Hepatology, 2003
- Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitroGastroenterology, 2002
- Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cellsGastroenterology, 2000
- An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosisGastroenterology, 2000
- Hepatocyte growth factor gene therapy of liver cirrhosis in ratsNature Medicine, 1999
- Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cellsHepatology, 1997